¼¼°èÀÇ ¸»¶ó¸®¾Æ ¹é½Å ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Çâ, ¾÷°è ºÐ¼® : ¹é½Å Á¾·ùº°, Åõ¿© °æ·Îº°, ´ë»ó Àα¸º°, ¿¹¹æ Á¢Á¾ ½ºÄÉÁÙº°, °³¹ß ´Ü°èº°, Áö¿ªº° - ½ÃÀå ¿¹Ãø(2025-2034³â)
Malaria Vaccines Market Size, Share, Trends, Industry Analysis Report: By Vaccine Type, Administration Route, Target Population, Immunization Schedule, Development Stage, and Region - Market Forecast, 2025-2034
»óǰÄÚµå
:
1671160
¸®¼Ä¡»ç
:
Polaris Market Research
¹ßÇàÀÏ
:
2025³â 02¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 114 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
Polaris Market ResearchÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é, ¼¼°è ¸»¶ó¸®¾Æ ¹é½Å ½ÃÀå ±Ô¸ð´Â 2034³â±îÁö 16¾ï 1,987¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ º¸°í¼´Â ÇöÀç ½ÃÀå ¿ªÇп¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÀλçÀÌÆ®¿Í ÇâÈÄ ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.
¸»¶ó¸®¾Æ´Â °¨¿°µÈ ¸ð±â¿¡ ¹°·Á »ç¶÷¿¡¼ »ç¶÷À¸·Î Àü¿°µÇ´Â ¿øÃæ¿¡ ÀÇÇØ ¹ß»ýÇÏ´Â »ý¸íÀ» À§ÇùÇÏ´Â ½É°¢ÇÑ Áúº´ÀÔ´Ï´Ù. ¸ð±â°¡ ¸Å°³ÇÏ´Â ÀÌ Áúº´Àº ¾î¸°ÀÌ¿Í ¼ºÀο¡°Ô ½É°¢ÇÑ Áúº´À» À¯¹ßÇÕ´Ï´Ù. ƯÈ÷ ÀÓ»êºÎ¿Í ¾î¸°ÀÌ´Â ¸»¶ó¸®¾Æ·Î ÀÎÇÑ ¹ß¿¿¡ Ãë¾àÇÕ´Ï´Ù. ÀÌ Áúº´À» ¿¹¹æÇϱâ À§ÇÑ ´Ù¾çÇÑ ¿¹¹æÃ¥À¸·Î´Â ¹æÃæ¸Á »ç¿ë, »ìÃæÁ¦ »ìÆ÷ µîÀÌ ÀÖ½À´Ï´Ù. ±×·¯³ª ÇöÀç Á¶»ç ¿¬±¸¿¡ µû¸£¸é °ïÃæÀº »ìÃæÁ¦¿¡ ¸é¿ªÀÌ ÀÖ°í, »ìÃæÁ¦´Â ÀÎü¿¡ ÇØ·Î¿î ¿µÇâÀ» ¹ÌÄ¡¸ç, ¸»¶ó¸®¾Æ ¿Àº ¾àÀÌ µèÁö ¾Ê´Â °ÍÀ¸·Î ¹àÇôÁö°í ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó ¿¬±¸ÀÚµé°ú Á¦¾àȸ»çµéÀº ´ëü ¿¹¹æ¹ýÀ¸·Î ¸»¶ó¸®¾Æ ¹é½ÅÀ» °³¹ßÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù.
Àü ¼¼°è ¸»¶ó¸®¾Æ ¹ßº´·üÀÇ Áõ°¡¿Í Á¦¾àȸ»çµéÀÇ Àú°¡Çü ¸»¶ó¸®¾Æ ¹é½Å Ãâ½Ã µî ¿©·¯ ¿äÀεéÀÌ ¸»¶ó¸®¾Æ ¹é½Å ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¸»¶ó¸®¾ÆÀÇ ¿µÇâ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ¿¬±¸°³¹ß(R&D)¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ³ë·ÂÀÌ ½ÃÀå °³Ã´À» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
ÀϺΠ¸»¶ó¸®¾Æ°¡ À¯ÇàÇÏ´Â °³¹ßµµ»ó±¹ÀÇ Ãë¾àÇÑ °ø±Þ¸Á ¹× À¯Åë¸Á ¹®Á¦¸¦ ÇØ°áÇϱâ À§ÇÑ Á¤ºÎ ±â°ü ¹× ¹Î°£ ´ÜüÀÇ °³¹ß Áõ°¡´Â ¸»¶ó¸®¾Æ ¹é½ÅÀÇ Ã¤ÅÃÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥ÀÇ Áõ°¡¿Í Çõ½ÅÀûÀÎ ¹é½Å ±â¼ú °³¹ß¿¡ ´ëÇÑ °Á¶´Â ÇâÈÄ ¸î ³â µ¿¾È ¸»¶ó¸®¾Æ ¹é½Å ½ÃÀå¿¡ ¸î °¡Áö ½ÃÀå ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¸»¶ó¸®¾Æ ¹é½Å ½ÃÀå : ºÐ¼® °³¿ä
¹é½Å À¯Çüº°·Î´Â RTS, S/AS01 ¹é½ÅÀÇ È¿´ÉÀ» ÀÔÁõÇÏ´Â ±¤¹üÀ§ÇÑ ÀÓ»ó ¿¬±¸ ¹× ÀÓ»ó½ÃÇè°ú ¾ÆÇÁ¸®Ä« ±¹°¡¿¡¼ÀÇ °³¹ß·Î ÀÎÇØ RTS, S/AS01 ºÐ¾ß°¡ 2024³â ¸»¶ó¸®¾Æ ¹é½Å ½ÃÀå ¸ÅÃâ¿¡¼ °¡Àå Å« ºñÁßÀ» Â÷ÁöÇß½À´Ï´Ù.
Åõ¿© °æ·Îº°·Î´Â R21/Matrix-M, RTS, S/AS01À» Æ÷ÇÔÇÑ ¸»¶ó¸®¾Æ ¹é½ÅÀÇ Åõ¿©¿¡ ±ÙÀ° ³» Åõ¿©°¡ °¡Àå ³Î¸® »ç¿ëµÇ¾î 2024³â ¸»¶ó¸®¾Æ ¹é½Å ½ÃÀå Á¡À¯À²Àº ±ÙÀ° ³» Åõ¿©°¡ ÁÖµµÇß½À´Ï´Ù.
ºÏ¹Ì´Â ¸»¶ó¸®¾Æ ¹é½Å °³¹ß ÇÁ·Î±×·¥¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ´Â ÁÖ¿ä Á¦¾à»çµéÀÇ °·ÂÇÑ Á¸Àç°¨°ú ¸»¶ó¸®¾Æ ¹é½Å R&D ÀÌ´Ï¼ÅÆ¼ºê¸¦ Áö¿øÇÏ´Â À¯¸®ÇÑ Á¤ºÎ ±ÔÁ¦ µµÀÔÀ¸·Î ÀÎÇØ 2024³â ¸»¶ó¸®¾Æ ¹é½Å ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ù.
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¸»¶ó¸®¾Æ ¹é½Å ½ÃÀåÀº 2025³âºÎÅÍ 2034³â±îÁö »ó´çÇÑ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â ÀÇ·á ÀÎÇÁ¶ó ±¸Ãà¿¡ ´ëÇÑ °ü½É Áõ°¡¿Í ºñ¿ë È¿À²ÀûÀÎ ¸»¶ó¸®¾Æ ¹é½Å °³¹ßÀ» À§ÇÑ Á¤ºÎ ¹× ¹Î°£ Á¶Á÷ °£ÀÇ Çù·Â °È¿¡ ±âÀÎÇÕ´Ï´Ù.
Instituto Butantan, Merck, PATH, GSK, Vaxart, Biovac, Pfizer, Inovio Pharmaceuticals, Bharat Biotech, University of Oxford, Intellia Therapeutics, Johnson & Johnson, Sanaria, and Takeda Pharmaceutical Company´Â ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷ Áß ÇϳªÀÔ´Ï´Ù.
¸ñÂ÷
Á¦1Àå ¼Ò°³
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå ºÐ¼® ¹æ¹ý
Á¦4Àå ¼¼°èÀÇ ¸»¶ó¸®¾Æ ¹é½Å ½ÃÀå ÀλçÀÌÆ®
½ÃÀå ÇöȲ
¸»¶ó¸®¾Æ ¹é½Å ½ÃÀå ¿ªÇÐ
¼ºÀå ÃËÁø¿äÀΰú ±âȸ
Àú¼Òµæ±¹ÀÇ ¸»¶ó¸®¾Æ ¸¸¿¬ È®´ë
Àڱݰú ÅõÀÚ Áõ°¡
¼ºÀå ¾ïÁ¦¿äÀΰú °úÁ¦
ÀǾàǰ °³¹ß°ú À¯Åë¿¡ ¼Ò¿äµÇ´Â °íºñ¿ë
PESTLE ºÐ¼®
¸»¶ó¸®¾Æ ¹é½Å ½ÃÀå ÀÀ¿ë µ¿Çâ
¹ë·ùüÀÎ ºÐ¼®
COVID-19ÀÇ ¿µÇ⠺м®
Á¦5Àå ¼¼°èÀÇ ¸»¶ó¸®¾Æ ¹é½Å ½ÃÀå : ¹é½Å Á¾·ùº°
ÁÖ¿ä ºÐ¼® °á°ú
¼Ò°³
PfSPZ
RTS,S/AS01¡¡
R21/Matrix-M
Á¦6Àå ¼¼°èÀÇ ¸»¶ó¸®¾Æ ¹é½Å ½ÃÀå : Åõ¿© °æ·Îº°
ÁÖ¿ä ºÐ¼® °á°ú
¼Ò°³
ÇÇÇÏ
±ÙÀ°³»
Á¦7Àå ¼¼°èÀÇ ¸»¶ó¸®¾Æ ¹é½Å ½ÃÀå : ´ë»ó Àα¸º°
ÁÖ¿ä ºÐ¼® °á°ú
¼Ò°³
À¯Çà Áö¿ª ¿©ÇàÀÚ
ÀÓ»êºÎ
5¼¼ ¹Ì¸¸ ¼Ò¾Æ
Á¦8Àå ¼¼°èÀÇ ¸»¶ó¸®¾Æ ¹é½Å ½ÃÀå : ¿¹¹æ Á¢Á¾ ½ºÄÉÁÙº°
ÁÖ¿ä ºÐ¼® °á°ú
¼Ò°³
ÀÏȸ Á¢Á¾
´Ùȸ Á¢Á¾
Ãß°¡ Á¢Á¾
Á¦9Àå ¼¼°èÀÇ ¸»¶ó¸®¾Æ ¹é½Å ½ÃÀå : °³¹ß ´Ü°èº°
ÁÖ¿ä ºÐ¼® °á°ú
¼Ò°³
ÀüÀÓ»ó
ÀÓ»ó½ÃÇè
Á¦10Àå ¼¼°èÀÇ ¸»¶ó¸®¾Æ ¹é½Å ½ÃÀå : Áö¿ªº°
ÁÖ¿ä ºÐ¼® °á°ú
¼Ò°³
¸»¶ó¸®¾Æ ¹é½Å ½ÃÀå Æò°¡ : Áö¿ªº°(2020-2034³â)
ºÏ¹Ì
ºÏ¹Ì : ¹é½Å Á¾·ùº°(2020-2034³â)
ºÏ¹Ì : Åõ¿© °æ·Îº°(2020-2034³â)
ºÏ¹Ì : ´ë»ó Àα¸º°(2020-2034³â)
ºÏ¹Ì : ¿¹¹æ Á¢Á¾ ½ºÄÉÁÙº°(2020-2034³â)
ºÏ¹Ì : °³¹ß ´Ü°èº°(2020-2034³â)
¹Ì±¹
ij³ª´Ù
À¯·´
À¯·´ : ¹é½Å Á¾·ùº°(2020-2034³â)
À¯·´ : Åõ¿© °æ·Îº°(2020-2034³â)
À¯·´ : ´ë»ó Àα¸º°(2020-2034³â)
À¯·´ : ¿¹¹æ Á¢Á¾ ½ºÄÉÁÙº°(2020-2034³â)
À¯·´ : °³¹ß ´Ü°èº°(2020-2034³â)
¿µ±¹
ÇÁ¶û½º
µ¶ÀÏ
ÀÌÅ»¸®¾Æ
½ºÆäÀÎ
³×´ú¶õµå
·¯½Ã¾Æ
±âŸ À¯·´
¾Æ½Ã¾ÆÅÂÆò¾ç
¾Æ½Ã¾ÆÅÂÆò¾ç : ¹é½Å Á¾·ùº°(2020-2034³â)
¾Æ½Ã¾ÆÅÂÆò¾ç : Åõ¿© °æ·Îº°(2020-2034³â)
¾Æ½Ã¾ÆÅÂÆò¾ç : ´ë»ó Àα¸º°(2020-2034³â)
¾Æ½Ã¾ÆÅÂÆò¾ç : ¿¹¹æ Á¢Á¾ ½ºÄÉÁÙº°(2020-2034³â)
¾Æ½Ã¾ÆÅÂÆò¾ç : °³¹ß ´Ü°èº°(2020-2034³â)
Áß±¹
Àεµ
¸»·¹À̽þÆ
ÀϺ»
Àεµ³×½Ã¾Æ
Çѱ¹
È£ÁÖ
±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ¹é½Å Á¾·ùº°(2020-2034³â)
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : Åõ¿© °æ·Îº°(2020-2034³â)
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ´ë»ó Àα¸º°(2020-2034³â)
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ¿¹¹æ Á¢Á¾ ½ºÄÉÁÙº°(2020-2034³â)
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : °³¹ß ´Ü°èº°(2020-2034³â)
»ç¿ìµð¾Æ¶óºñ¾Æ
¾Æ¶ø¿¡¹Ì¸®Æ®
À̽º¶ó¿¤
³²¾ÆÇÁ¸®Ä«°øÈ±¹
±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
¶óƾ¾Æ¸Þ¸®Ä«
¶óƾ¾Æ¸Þ¸®Ä« : ¹é½Å Á¾·ùº°(2020-2034³â)
¶óƾ¾Æ¸Þ¸®Ä« : Åõ¿© °æ·Îº°(2020-2034³â)
¶óƾ¾Æ¸Þ¸®Ä« : ´ë»ó Àα¸º°(2020-2034³â)
¶óƾ¾Æ¸Þ¸®Ä« : ¿¹¹æ Á¢Á¾ ½ºÄÉÁÙº°(2020-2034³â)
¶óƾ¾Æ¸Þ¸®Ä« : °³¹ß ´Ü°èº°(2020-2034³â)
¸ß½ÃÄÚ
ºê¶óÁú
¾Æ¸£ÇîÆ¼³ª
±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
Á¦11Àå °æÀï ±¸µµ
»ç¾÷ È®´ë¡¤±â¾÷ Àμö ºÐ¼®
Á¦ÈÞ/Çù¾÷/ÇÕÀÇ/°ø°³
Á¦12Àå ±â¾÷ °³¿ä
Instituto Butantan
Merck
PATH
GSK
Vaxart
Biovac
Pfizer
Inovio Pharmaceuticals
Bharat Biotech
University of Oxford
Intellia Therapeutics
Johnson & Johnson
Sanaria
Takeda Pharmaceutical Company
ksm
¿µ¹® ¸ñÂ÷
The global malaria vaccines market size is expected to reach USD 1,619.87 million by 2034, according to a new study by Polaris Market Research. The report "Malaria Vaccines Market Size, Share, Trends, Industry Analysis Report: By Vaccine Type, Administration Route (Subcutaneous and Intramuscular), Target Population, Immunization Schedule, Development Stage, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Malaria is a serious, life-threatening disease caused by Plasmodium parasite, which is transmitted from human to human by the bite of infected mosquitoes. This mosquito-borne illness causes severe disease in kids and adults. Pregnant women and children are particularly vulnerable to the fever caused by malaria. Various precautions to control the disease include the use of insect nets and spraying of pesticides. However, current research studies have shown that insects are immune to pesticides, pesticides have harmful effects on human beings, and malaria fever is becoming immune to medications. In response to these challenges, researchers and pharmaceutical companies have been working on the development of malaria vaccines as an alternative method of prevention.
Several factors, such as the rising incidence of malaria worldwide and the introduction of low-cost malaria vaccines by pharma companies globally, are driving the malaria vaccines market growth. Rising awareness about the disease's consequences and ongoing research and development (R&D) initiatives are further supporting the market development.
Growing efforts by government and private organizations to address the issues of weak supply chains and distribution networks in some malaria-endemic developing countries are expected to boost the adoption of malaria vaccines. Rising inoculation programs and emphasis on the development of innovative vaccine technologies are expected to provide several malaria vaccines market opportunities in the coming years.
Key Highlights of Malaria Vaccines Market Report
Based on vaccine type, the RTS,S/AS01 segment held the largest share of the malaria vaccines market revenue in 2024, owing to the extensive clinical research and trials demonstrating the efficacy of RTS, S/AS01 vaccines, and their rollout in various African countries.
By administration route, the intramuscular segment led the malaria vaccines market share in 2024 as intramuscular is the most widely used route for administrating malaria vaccines, including R21/Matrix-M and RTS,S/AS01.
North America led the market for malaria vaccines in 2024, driven by the strong presence of leading pharma companies with significant investments in malaria vaccine development programs and the introduction of favorable government regulations supporting malaria vaccine R&D initiatives.
The Middle East & Africa malaria vaccines market is projected to witness a significant CAGR from 2025 to 2034, driven by the rising focus on improving healthcare infrastructure and enhanced collaborations between government and private organizations to develop cost-effective malaria vaccines.
Instituto Butantan, Merck, PATH, GSK, Vaxart, Biovac, Pfizer, Inovio Pharmaceuticals, Bharat Biotech, University of Oxford, Intellia Therapeutics, Johnson & Johnson, Sanaria, and Takeda Pharmaceutical Company are a few of the key players in the market.
Polaris Market Research has segmented the malaria vaccines market research report on the basis of vaccine type, administration route, target population, immunization schedule, development stage, and region:
By Vaccine Type Outlook (Revenue - USD Million, 2020-2034)
PfSPZ
RTS,S/AS01
R21/Matrix-M
By Administration Route Outlook (Revenue - USD Million, 2020-2034)
Subcutaneous
Intramuscular
By Target Population Outlook (Revenue - USD Million, 2020-2034)
Travelers to Endemic Areas
Pregnant Women
Children under 5 Years
By Immunization Schedule Outlook (Revenue - USD Million, 2020-2034)
Single Dose
Multi-Dose
Booster Doses
By Development Stage Outlook (Revenue - USD Million, 2020-2034)
Preclinical
Clinical Trials
By Regional Outlook (Revenue - USD Million, 2020-2034)
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Table of Contents
1. Introduction
1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders
2. Executive Summary
3. Research Methodology
3.1. Overview
3.2. Data Sources
3.2.1. Primary Sources
3.2.2. Secondary Sources
4. Global Malaria Vaccines Market Insights
4.1. Malaria Vaccines Market - Application Snapshot
4.2. Malaria Vaccines Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Growing Prevalence of Malaria in Low-Income Countries
4.2.1.2. Increasing Funding and Investment
4.2.2. Restraints and Challenges
4.2.2.1. High Cost of Drug Development and Distribution
4.3. Porter's Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry Among Existing Firms (High)
4.4. PESTEL Analysis
4.5. Malaria Vaccines Market Application Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis
5. Global Malaria Vaccines Market, by Vaccine Type
5.1. Key Findings
5.2. Introduction
5.2.1. Global Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
5.3. PfSPZ
5.3.1. Global Malaria Vaccines Market, by PfSPZ, by Region, 2020-2034 (USD Million)
5.4. RTS,S/AS01
5.4.1. Global Malaria Vaccines Market, by RTS,S/AS01, by Region, 2020-2034 (USD Million)
5.5. R21/Matrix-M
5.5.1. Global Malaria Vaccines Market, by R21/Matrix-M, by Region, 2020-2034 (USD Million)
6. Global Malaria Vaccines Market, by Administration Route
6.1. Key Findings
6.2. Introduction
6.2.1. Global Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
6.3. Subcutaneous
6.3.1. Global Malaria Vaccines Market, by Subcutaneous, by Region, 2020-2034 (USD Million)
6.4. Intramuscular
6.4.1. Global Malaria Vaccines Market, by Intramuscular, by Region, 2020-2034 (USD Million)
7. Global Malaria Vaccines Market, by Target Population
7.1. Key Findings
7.2. Introduction
7.2.1. Global Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
7.3. Travelers to Endemic Areas
7.3.1. Global Malaria Vaccines Market, by Travelers to Endemic Areas, by Region, 2020-2034 (USD Million)
7.4. Pregnant Women
7.4.1. Global Malaria Vaccines Market, by Pregnant Women, by Region, 2020-2034 (USD Million)
7.5. Children Under 5 years
7.5.1. Global Malaria Vaccines Market, by Children Under 5 years, by Region, 2020-2034 (USD Million)
8. Global Malaria Vaccines Market, by Immunization Schedule
8.1. Key Findings
8.2. Introduction
8.2.1. Global Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
8.3. Single Dose
8.3.1. Global Malaria Vaccines Market, by Single Dose, by Region, 2020-2034 (USD Million)
8.4. Multi-Dose
8.4.1. Global Malaria Vaccines Market, by Multi-Dose, by Region, 2020-2034 (USD Million)
8.5. Booster Doses
8.5.1. Global Malaria Vaccines Market, by Booster Doses, by Region, 2020-2034 (USD Million)
9. Global Malaria Vaccines Market, by Development Stage
9.1. Key Findings
9.2. Introduction
9.2.1. Global Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
9.3. Preclinical
9.3.1. Global Malaria Vaccines Market, by Preclinical, by Region, 2020-2034 (USD Million)
9.4. Clinical Trials
9.4.1. Global Malaria Vaccines Market, by Clinical Trials, by Region, 2020-2034 (USD Million)
10. Global Malaria Vaccines Market, by Geography
10.1. Key Findings
10.2. Introduction
10.2.1. Malaria Vaccines Market Assessment, by Geography, 2020-2034 (USD Million)
10.3. Malaria Vaccines Market - North America
10.3.1. North America: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
10.3.2. North America: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
10.3.3. North America: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
10.3.4. North America: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
10.3.5. North America: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
10.3.6. Malaria Vaccines Market - US
10.3.6.1. US: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
10.3.6.2. US: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
10.3.6.3. US: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
10.3.6.4. US: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
10.3.6.5. US: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
10.3.7. Malaria Vaccines Market - Canada
10.3.7.1. Canada: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
10.3.7.2. Canada: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
10.3.7.3. Canada: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
10.3.7.4. Canada: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
10.3.7.5. Canada: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
10.4. Malaria Vaccines Market - Europe
10.4.1. Europe: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
10.4.2. Europe: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
10.4.3. Europe: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
10.4.4. Europe: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
10.4.5. Europe: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
10.4.6. Malaria Vaccines Market - UK
10.4.6.1. UK: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
10.4.6.2. UK: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
10.4.6.3. UK: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
10.4.6.4. UK: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
10.4.6.5. UK: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
10.4.7. Malaria Vaccines Market - France
10.4.7.1. France: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
10.4.7.2. France: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
10.4.7.3. France: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
10.4.7.4. France: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
10.4.7.5. France: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
10.4.8. Malaria Vaccines Market - Germany
10.4.8.1. Germany: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
10.4.8.2. Germany: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
10.4.8.3. Germany: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
10.4.8.4. Germany: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
10.4.8.5. Germany: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
10.4.9. Malaria Vaccines Market - Italy
10.4.9.1. Italy: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
10.4.9.2. Italy: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
10.4.9.3. Italy: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
10.4.9.4. Italy: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
10.4.9.5. Italy: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
10.4.10. Malaria Vaccines Market - Spain
10.4.10.1. Spain: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
10.4.10.2. Spain: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
10.4.10.3. Spain: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
10.4.10.4. Spain: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
10.4.10.5. Spain: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
10.4.11. Malaria Vaccines Market - Netherlands
10.4.11.1. Netherlands: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
10.4.11.2. Netherlands: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
10.4.11.3. Netherlands: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
10.4.11.4. Netherlands: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
10.4.11.5. Netherlands: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
10.4.12. Malaria Vaccines Market - Russia
10.4.12.1. Russia: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
10.4.12.2. Russia: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
10.4.12.3. Russia: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
10.4.12.4. Russia: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
10.4.12.5. Russia: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
10.4.13. Malaria Vaccines Market - Rest of Europe
10.4.13.1. Rest of Europe: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
10.4.13.2. Rest of Europe: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
10.4.13.3. Rest of Europe: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
10.4.13.4. Rest of Europe: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
10.4.13.5. Rest of Europe: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
10.5. Malaria Vaccines Market - Asia Pacific
10.5.1. Asia Pacific: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
10.5.2. Asia Pacific: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
10.5.3. Asia Pacific: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
10.5.4. Asia Pacific: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
10.5.5. Asia Pacific: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
10.5.6. Malaria Vaccines Market - China
10.5.6.1. China: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
10.5.6.2. China: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
10.5.6.3. China: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
10.5.6.4. China: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
10.5.6.5. China: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
10.5.7. Malaria Vaccines Market - India
10.5.7.1. India: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
10.5.7.2. India: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
10.5.7.3. India: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
10.5.7.4. India: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
10.5.7.5. India: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
10.5.8. Malaria Vaccines Market - Malaysia
10.5.8.1. Malaysia: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
10.5.8.2. Malaysia: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
10.5.8.3. Malaysia: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
10.5.8.4. Malaysia: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
10.5.8.5. Malaysia: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
10.5.9. Malaria Vaccines Market - Japan
10.5.9.1. Japan: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
10.5.9.2. Japan: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
10.5.9.3. Japan: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
10.5.9.4. Japan: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
10.5.9.5. Japan: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
10.5.10. Malaria Vaccines Market - Indonesia
10.5.10.1. Indonesia: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
10.5.10.2. Indonesia: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
10.5.10.3. Indonesia: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
10.5.10.4. Indonesia: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
10.5.10.5. Indonesia: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
10.5.11. Malaria Vaccines Market - South Korea
10.5.11.1. South Korea: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
10.5.11.2. South Korea: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
10.5.11.3. South Korea: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
10.5.11.4. South Korea: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
10.5.11.5. South Korea: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
10.5.12. Malaria Vaccines Market - Australia
10.5.12.1. Australia: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
10.5.12.2. Australia: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
10.5.12.3. Australia: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
10.5.12.4. Australia: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
10.5.12.5. Australia: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
10.5.13. Malaria Vaccines Market - Rest of Asia Pacific
10.5.13.1. Rest of Asia Pacific: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
10.5.13.2. Rest of Asia Pacific: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
10.5.13.3. Rest of Asia Pacific: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
10.5.13.4. Rest of Asia Pacific: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
10.5.13.5. Rest of Asia Pacific: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
10.6. Malaria Vaccines Market - Middle East & Africa
10.6.1. Middle East & Africa: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
10.6.2. Middle East & Africa: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
10.6.3. Middle East & Africa: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
10.6.4. Middle East & Africa: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
10.6.5. Middle East & Africa: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
10.6.6. Malaria Vaccines Market - Saudi Arabia
10.6.6.1. Saudi Arabia: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
10.6.6.2. Saudi Arabia: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
10.6.6.3. Saudi Arabia: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
10.6.6.4. Saudi Arabia: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
10.6.6.5. Saudi Arabia: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
10.6.7. Malaria Vaccines Market - UAE
10.6.7.1. UAE: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
10.6.7.2. UAE: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
10.6.7.3. UAE: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
10.6.7.4. UAE: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
10.6.7.5. UAE: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
10.6.8. Malaria Vaccines Market - Israel
10.6.8.1. Israel: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
10.6.8.2. Israel: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
10.6.8.3. Israel: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
10.6.8.4. Israel: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
10.6.8.5. Israel: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
10.6.9. Malaria Vaccines Market - South Africa
10.6.9.1. South Africa: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
10.6.9.2. South Africa: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
10.6.9.3. South Africa: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
10.6.9.4. South Africa: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
10.6.9.5. South Africa: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
10.6.10. Malaria Vaccines Market - Rest of Middle East & Africa
10.6.10.1. Rest of Middle East & Africa: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
10.6.10.2. Rest of Middle East & Africa: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
10.6.10.3. Rest of Middle East & Africa: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
10.6.10.4. Rest of Middle East & Africa: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
10.6.10.5. Rest of Middle East & Africa: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
10.7. Malaria Vaccines Market - Latin America
10.7.1. Latin America: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
10.7.2. Latin America: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
10.7.3. Latin America: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
10.7.4. Latin America: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
10.7.5. Latin America: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
10.7.6. Malaria Vaccines Market - Mexico
10.7.6.1. Mexico: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
10.7.6.2. Mexico: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
10.7.6.3. Mexico: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
10.7.6.4. Mexico: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
10.7.6.5. Mexico: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
10.7.7. Malaria Vaccines Market - Brazil
10.7.7.1. Brazil: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
10.7.7.2. Brazil: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
10.7.7.3. Brazil: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
10.7.7.4. Brazil: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
10.7.7.5. Brazil: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
10.7.8. Malaria Vaccines Market - Argentina
10.7.8.1. Argentina: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
10.7.8.2. Argentina: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
10.7.8.3. Argentina: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
10.7.8.4. Argentina: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
10.7.8.5. Argentina: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
10.7.9. Malaria Vaccines Market - Rest of Latin America
10.7.9.1. Rest of Latin America: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
10.7.9.2. Rest of Latin America: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
10.7.9.3. Rest of Latin America: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
10.7.9.4. Rest of Latin America: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
10.7.9.5. Rest of Latin America: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
11. Competitive Landscape
11.1. Expansion and Acquisition Analysis
11.1.1. Expansion
11.1.2. Acquisitions
11.2. Partnerships/Collaborations/Agreements/Exhibitions
12. Company Profiles
12.1. Instituto Butantan
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Benchmarking
12.1.4. Recent Development
12.2. Merck
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Product Benchmarking
12.2.4. Recent Development
12.3. PATH
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Product Benchmarking
12.3.4. Recent Development
12.4. GSK
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Product Benchmarking
12.4.4. Recent Development
12.5. Vaxart
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Product Benchmarking
12.5.4. Recent Development
12.6. Biovac
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Product Benchmarking
12.6.4. Recent Development
12.7. Pfizer
12.7.1. Company Overview
12.7.2. Financial Performance
12.7.3. Product Benchmarking
12.7.4. Recent Development
12.8. Inovio Pharmaceuticals
12.8.1. Company Overview
12.8.2. Financial Performance
12.8.3. Product Benchmarking
12.8.4. Recent Development
12.9. Bharat Biotech
12.9.1. Company Overview
12.9.2. Financial Performance
12.9.3. Product Benchmarking
12.9.4. Recent Development
12.10. University of Oxford
12.10.1. Company Overview
12.10.2. Financial Performance
12.10.3. Product Benchmarking
12.10.4. Recent Development
12.11. Intellia Therapeutics
12.11.1. Company Overview
12.11.2. Financial Performance
12.11.3. Product Benchmarking
12.11.4. Recent Development
12.12. Johnson & Johnson
12.12.1. Company Overview
12.12.2. Financial Performance
12.12.3. Product Benchmarking
12.12.4. Recent Development
12.13. Sanaria
12.13.1. Company Overview
12.13.2. Financial Performance
12.13.3. Product Benchmarking
12.13.4. Recent Development
12.14. Takeda Pharmaceutical Company
12.14.1. Company Overview
12.14.2. Financial Performance
12.14.3. Product Benchmarking
12.14.4. Recent Development
°ü·ÃÀÚ·á